AVertto

AVerttoAVertto
AVertto

AVertto

Developing a non-invasive device to detect silent strokes in high-risk populations.

Website
DR 52021Active12Tel Aviv, Israel
Rate
Advertise here

About

AVertto develops medical technology that monitors, detects, and alerts to critical neurovascular events, such as stroke, by continuously analyzing carotid blood pressure waveforms. Their first commercial device, AMIT301, uses carotid biological mimicry to detect hemodynamic changes in real-time, providing clinical decision support for sedated ICU patients. This technology aims to give clinicians more time for intervention before irreversible neurological damage occurs.
HEADCOUNT
12
DOMAIN RATING
5
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does AVertto do?

AVertto develops medical technology that monitors, detects, and alerts to critical neurovascular events, such as stroke, by continuously analyzing carotid blood pressure waveforms. Their first commercial device, AMIT301, uses carotid biological mimicry to detect hemodynamic changes in real-time, providing clinical decision support for sedated ICU patients. This technology aims to give clinicians more time for intervention before irreversible neurological damage occurs.

Where is AVertto headquartered?

AVertto is headquartered in Tel Aviv, Israel.

When was AVertto founded?

AVertto was founded in 2021.

What industry does AVertto operate in?

AVertto operates in Healthcare, Non-invasive, Blood Pressure, Strokes, HealthTech, MedTech.

How many employees does AVertto have?

AVertto has approximately 12 people on record.

What is AVertto's revenue?

StartupHub estimates AVertto's annual revenue at $3.2M (range $1.9M to $6.1M, 63% confidence), based on comparable companies in the sector.